Table 2.
The Relationship Between p16 and Clinicalpathological Parameters of Patients
| Clinicopathological Findings | p16-IHC | P | |
|---|---|---|---|
| Positive (n = 100) | Negative (n = 210) | ||
| Age at diagnosis, years | |||
| <51 | 29 | 91 | 0.02 |
| ≥51 | 71 | 119 | 0.02 |
| FIGO stage | |||
| I/II | 40 | 36 | <0.01 |
| III/IV | 60 | 174 | <0.01 |
| Serum CA-125 level (U/mL) | |||
| <35 | 20 | 22 | 0.03 |
| ≥35 | 80 | 188 | 0.03 |
| Histopathological differentiation | |||
| Well | 70 | 64 | <0.01 |
| Moderate | 20 | 82 | 0.001 |
| Poor | 10 | 64 | <0.01 |
| Histology type | |||
| Serous adenocarcinoma | 80 | 128 | 0.001 |
| Mucinous adenocarcinoma | 9 | 39 | <0.01 |
| Others | 11 | 43 | <0.01 |
| Event after initial treatment | |||
| 3 years overall survival rate | 80% (80) | 62.8% (132) | <0.05 |
| 5 years overall survival rate | 72% (72) | 53.3% (112) | <0.05 |
| HPV status | 76 | 2 | |
| HPV positive | 24 | 208 | <0.05 |
| HPV negative | <0.05 | ||